Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group.

OBJECTIVES: We sought to prospectively and randomly compare survival with clinical and hemodynamic variables in patients with congestive heart failure (CHF) treated with standard versus high doses of enalapril. BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors produce hemodynamic and symptomatic benefits in patients with CHF, but there is still controversy about the optimal dose in this clinical setting. METHODS: Two hundred and forty-eight patients with advanced CHF (age 56.3+/-12 years) were randomized to receive a maximal tolerated dose of enalapril, up to 20 mg/day in group 1 (mean dose achieved 17.9+/-4.3 mg/day, n = 122) and 60 mg/day in group 2 (mean dose achieved 42+/-19.3 mg/day, n = 126). RESULTS: At enrollment, patients in group 1 were in New York Heart Association (NYHA) functional class 2.6+/-0.7 and had a mean systolic blood pressure (SBP) of 117+/-18 mm Hg, a mean heart rate (HR) of 85+/-16 beats/min and a left ventricular ejection fraction (LVEF) of 20.0+/-9.8%. In group 2, patients were in NYHA class 2.6+/-0.7; their SBP was 118+/-17 mm Hg, HR 83+/-15 beats/min and LVEF 18.8+/-8.1%. There were no significant differences in these characteristics between the two groups of patients at enrollment. After 12 months of follow-up, 22 (18%) of 122 patients in group 1 and 23 (18%) of 126 patients in group 2 had died (p = 0.995, with 80% power of the study to detect a delta difference of 13%). The NYHA class was the same (1.9+/-0.7) in both groups; SBP was 111+/-16 and 111+/-17 mm Hg, HR 77+/-12 and 79+/-13 beats/min and LVEF 31+/-19% and 30+/-12% in groups 1 and 2, respectively. These differences were not statistically significant. The study had a power of 80% to detect (p = 0.05) the following changes: 13% in death rate, 0.25 units in NYHA class, 6 mm Hg in SBP, 5 beats/min in HR and 6% in LVEF. CONCLUSIONS: No significant differences were found in survival and clinical and hemodynamic variables between patients receiving standard and those receiving high doses of enalapril.

Left ventricular diastolic filling changes during dipyridamole-induced ischaemia. An echo-Doppler study.

OBJECTIVE: To evaluate the usefulness of the Doppler assessment of left ventricular diastolic functioning during dipyridamole-induced ischaemia in patients with coronary artery disease (CAD). METHODS: We studied 28 patients with angiographically proven CAD [18 men, aged 62 +/- 7 years (mean +/- SD)] and 18 normal subjects (12 men, aged 59 +/- 7.5 years). Two-dimensional and transmitral flow Doppler echocardiography studies were performed at baseline and after intravenous administration of a high dose of dipyridamole (0.84 mg/kg during 10 min). Left ventricular wall motion was evaluated by two-dimensional Doppler echocardiography, with the left ventricle divided into a 16-segment model, whereas peak velocities of early and late diastolic flow, the early:late diastolic flow ratio and the deceleration rate of early diastolic flow were determined from transmitral flow Doppler echocardiography. RESULTS: Sixteen patients developed new wall-motion abnormalities (WMA), whereas the remaining 12 patients and the controls did not. Multivariate logistic regression analysis was performed to identify which of the parameters had independent diagnostic value for revealing CAD. WMA was entered at the first step and yielded a 57% sensitivity and 100% specificity; the changes in deceleration rate were entered as the second step, which improved the sensitivity to 85.5%, and reduced the specificity to 83% and raised the overall accuracy to 85% from 70% for WMA alone. More specifically, the sensitivity improved from 37.5, 63.5 and 65.5% to 62.5, 91 and 100%, respectively, for patients with one-, two- and three-vessel disease. The cut-off value of the change in deceleration rate was 7%. CONCLUSIONS: Patients could be classified as having CAD either if they developed new WMA or if the deceleration rate of early diastolic flow during dipyridamole-stress echocardiography increased by more than 7% compared with the rest value.

Comparison of angiographic findings, risk factors, and long term follow-up between young and old patients with a history of myocardial infarction.

We compared the angiographic findings, coronary risk factors and five years prognosis in 200 patients < or =45, and 260 patients >45 years old who where admitted with an acute myocardial infarction. We found that family history and smoking were the most common risk factors in patients < or =45 years old P<0.04, P<0.0001, respectively, and hypertension and diabetes mellitus were more prevalent in patients >45 years, P<0.00001 for both. Young patients had a higher incidence of normal coronary arteries and a lesser one of triple vessel disease in comparison with old ones P<0.001 and P<0.04, respectively. There was also a tendency for young patients to have a higher frequency of single vessel disease. The long-term prognosis was favourable in the younger age group since the survival rate was much better, as well as the quality of life. Death in the young patients seems to be very often electrical owing to sudden ventricular fibrillation, whereas death in the elderly is more often associated with congestive heart failure.

Combined protocols for myocardial perfusion imaging in patients with hypertension.

OBJECTIVE: Patients diagnosed previously with hypertension submitted to exercise testing for myocardial scintigraphy often respond with excessive elevation of the blood pressure, even when baseline blood pressure is normal, resulting in interruption of the test or false positive results for coronary artery disease. The aim of this study was to evaluate the haemodynamic changes and the safety of the combined examination protocols of dipyridamole plus handgrip exercise and of dipyridamole plus symptom-limited exercise testing on a treadmill in patients with hypertension. METHODS AND RESULTS: We performed scintigraphic myocardial single photon emission computed tomography in 240 patients with hypertension as follows: in 27 patients who were administered dipyridamole alone, in 126 patients who were administered dipyridamole and were also submitted to isometric handgrip exercise and in 87 patients who were administered dipyridamole and were also submitted to treadmill, symptom-limited exercise (modified Bruce protocol). Mean systolic blood pressure, mean diastolic blood pressure and heart rate did not rise excessively in patients submitted to exercise testing (192 +/- 18 mm Hg, 106 +/- 14 mm Hg and 111 +/- 21 bpm for the dipyridamole plus handgrip group and 180 +/- 28 mm Hg, 104 +/- 10 mm Hg and 149 +/- 19 bpm for the dipyridamole plus treadmill group, respectively), with two patients from each exercise group presenting a maximum systolic blood pressure higher than 220 mm Hg and no subsequent major cardiac complications (such as death, myocardial infarction, unstable angina or life-threatening arrhythmia). Moreover, patients in these exercise groups experienced fewer non-cardiac side effects than with dipyridamole alone, while attaining a good level of exercise stress. CONCLUSIONS: Both combined dipyridamole and exercise protocols for scintigraphic myocardial single photon emission computed tomography in patients with hypertension are safe and increase heart rate without an excessive elevation in blood pressure. Consequently, they can be recommended for clinical use. Dipyridamole combined with treadmill, symptom-limited exercise would be the first choice, with dipyridamole and isometric handgrip exercise reserved for patients with physical handicaps.